FDA Enables Generic Insulins with Lower Prices
Insulin Nation
MARCH 26, 2020
These critical therapies often carry a heavy price tag; the cost of insulin has risen over the past decade. But Glumetza, an extended-release version covered by secondary patents, will cost a patient as much as $600 a month versus the few dollars a month they’d pay for metformin. Biosimilar Drugs ‘Interchangeable Products’.
105 
Let's personalize your content